Advancing six business strategies under Vision 2030
First written in FY2020. 7 of 16 entries say "Restated". Latest entry: FY2027-H1.
No other company in this theme has enough history to compare yet.
- FY2027-H1RestatedAnnual report
「The Company has also adopted “Connect for Well-being & Longevity” and will work through its activities to realize a sustainable society in which people around the world can live healthy, happy and longer lives.」
The direction of the previous Vision 2030 and six business areas has been reconfirmed as “Connect for Well-being & Longevity.” - 2026-08-06Cited as achievedResults
「Among domestic group companies, ROHTO NITTEN CO., LTD., Qualitech Pharma Co., Ltd. and Tento Pharmaceutical Co., Ltd. contributed to higher revenue.」
The Company has reported that ROHTO NITTEN, Qualitech Pharma and Tento Pharmaceutical contributed to higher domestic revenue. - FY2026AdvancedAnnual report
「Under the three basic strategies established in this growth strategy, “strengthening business earning power,” “deepening and expanding technological and product capabilities,” and “building the foundation for the medical business,” the Company aims to realize a well-being-oriented society.」
The previous Vision 2030 and six business strategies have been defined through the three basic strategies, four business segments and six business areas of the “Medium- to Long-Term Growth Strategy 2025–2035.” - FY2026-H1ReframedAnnual report
「Against this backdrop, on 13 May 2025 we announced the “ROHTO Group Medium- to Long-Term Growth Strategy 2025–2035” and the “Management Policy for Achieving Long-Term Growth.”」
The previous comprehensive management vision 2030 and six business strategies have been reorganized as the “Medium- to Long-Term Growth Strategy 2025–2035” and a management policy with a long-term perspective. - FY2025-H1AdvancedAnnual report
「Subsequently, Soar R2M Pte. Ltd. exercised its right under Section 215(1) of the Singapore Companies Act to compulsorily acquire, at the offer price, the shares held by shareholders who had not accepted the tender offer, thereby making the company a wholly owned subsidiary dated 29 August 2024.」
The Company completed the conversion of Eu Yan Sang International Ltd., acquired as a concrete step toward Vision 2030's Asian OTC pharmaceuticals and food businesses, into a wholly owned subsidiary on 29 August 2024. - FY2024AdvancedAnnual report
「At a meeting of the Board of Directors held on 4 April 2024, the Company resolved to make Eu Yan Sang International Ltd., a Singapore-based manufacturer and seller of traditional Chinese medicines, a subsidiary, and completed the acquisition of its shares on 3 June 2024.」
As a concrete step toward Vision 2030's OTC pharmaceuticals, food and Asia businesses, the Company acquired 85.91% of the voting rights in Eu Yan Sang International Ltd. It aims to combine the company's products and brand strength in Asia with the Company's research, technology development and sales capabilities. - FY2024-Q3RestatedAnnual report
「Against this backdrop, our Group has adopted the slogan “Connect for Well-being” so that people around the world can enjoy happy, smiling lives, physically and mentally vibrant, across a range of life stages, and is working to further enhance corporate value toward realizing its Comprehensive Management Vision 2030.」
The business development initiatives toward realizing comprehensive management vision 2030 have been reconfirmed. - FY2024-Q2RestatedAnnual report
「Against this backdrop, our Group has adopted the slogan “Connect for Well-being” so that people around the world can enjoy happy, smiling lives, physically and mentally vibrant, across a range of life stages, and is working to further enhance corporate value toward realizing its Comprehensive Management Vision 2030.」
The business development initiatives toward realizing Vision 2030 have been reconfirmed. - FY2024-Q1RestatedAnnual report
「Against this backdrop, our Group has adopted the slogan “Connect for Well-being” so that people around the world can enjoy happy, smiling lives, physically and mentally vibrant, across a range of life stages, and is working to further enhance corporate value toward realizing its Comprehensive Management Vision 2030.」
The business development initiatives toward realizing Vision 2030 have been reconfirmed. - FY2023RestatedAnnual report
「The Company is devoting its full efforts to advancing the comprehensive management vision 2030, “Connect for Well-being,” established in 2019. It aims for sustainable growth through decisions that involve taking bold risks and management that can respond flexibly to change, while actively investing in six business areas centered on its core OTC pharmaceutical and skincare businesses to drive innovation.」
The Company's commitment to Vision 2030 and active investment in six business areas have been reconfirmed. OTC pharmaceuticals, skincare, functional foods, prescription ophthalmology, regenerative medicine and CDMO are described together with individual targets and initiatives. - FY2023-Q2RestatedAnnual report
「The Group has adopted the slogan “Connect for Well-being” and is working to realize its comprehensive management vision 2030 while seeking to enhance corporate value further, so that people around the world can enjoy healthy, vibrant and fulfilling lives with smiles at every stage of life.」
The business development initiatives toward realizing Vision 2030 have been reconfirmed. - FY2023-Q1RestatedAnnual report
「The Group has adopted the slogan “Connect for Well-being” and is working to realize its comprehensive management vision 2030 while seeking to enhance corporate value further, so that people around the world can enjoy healthy, vibrant and fulfilling lives with smiles at every stage of life.」
The business development initiatives toward realizing Vision 2030 have been reconfirmed. - FY2022-Q3AdvancedAnnual report
「In addition, 株式会社日本点眼薬研究所, クオリテックファーマ㈱ and 天藤製薬㈱, which became a subsidiary in August 2021, contributed to higher sales.」
In connection with the business expansion under Vision 2030, the specific post-acquisition result that 天藤製薬, which became a subsidiary in August 2021, contributed to higher sales in the Japan segment has been disclosed. - FY2022-Q2AdvancedAnnual report
「The Company aims to become a leading OTC pharmaceutical company in Japan as part of its comprehensive management vision 2030 established in 2019. It decided to acquire the shares because the transaction would represent a major step toward realizing comprehensive management vision 2030 and would enable further business expansion by leveraging the Company's overseas network. Business combination date: 31 August 2021 Voting rights acquired: 67.19%」
As a concrete step toward Vision 2030's goal of becoming a leading OTC pharmaceutical company, the Company acquired 天藤製薬 on 31 August 2021 and made it a consolidated subsidiary with a 67.19% voting interest. Expansion of the business by leveraging its overseas network was also cited as a reason for the acquisition. - FY2021AdvancedAnnual report
「“Developing the prescription ophthalmology channel as an eye-care leader and achieving early monetization”」
The six businesses under Vision 2030 have been detailed across OTC pharmaceuticals, skincare, functional foods, prescription ophthalmology, regenerative medicine and CDMO, together with specific brand targets, subsidiaries, research and development, partnerships, and sales and manufacturing platforms. - FY2020First statedAnnual report
「The specific issues to be addressed are as follows.」
Under its comprehensive management vision through 2030, the Company has established six business strategies: OTC pharmaceuticals, skincare, functional foods, prescription ophthalmology, regenerative medicine, and contract development and manufacturing.